---
title: "Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised[comma] controlled[comma] open-label[comma] phase 3b trial."
date: 2022-04-29
enddate:
---

Published in: *The Lancet. Neurology*

DOI: 10.1016/S1474-4422(22)00143-0

This article is not available in Open Access


